Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2008

01-07-2008 | Special Feature

PET/CT supports breast cancer diagnosis and treatment

Authors: Mitsuhiro Hayashi, Koji Murakami, Testsunari Oyama, Yasushi Domeki, Shingo Hagiwara, Daisuke Katsumata, Masakatsu Sunagawa

Published in: Breast Cancer | Issue 3/2008

Login to get access

Abstract

The application of positron emission tomography with 18F fluoro-2-deoxy-d-glucose (FDG-PET) has remarkably improved the management of cancer patients. However, some caution is necessary in the interpretation of FDG-PET images. Because of its low spatial resolution, it is difficult to identify the anatomical location of radiotracer uptake and to distinguish between normal physiological accumulation and pathological uptake. A novel combined PET/CT system has been developed that improves the capacity to correctly localize and interpret FDG uptake. Although only a few studies have been conducted on the potential role of PET/CT in the management of breast cancer patients, the advantage of this modality compared with PET alone should be relevant for application in the field of breast cancer. In this review, we describe the clinical impact of PET/CT on breast cancer diagnosis compared with PET alone with respect to disease restaging, treatment monitoring, preoperative staging and primary diagnosis. In addition, the possible role of PET/CT with iodine contrast is noted for evaluation of intra-ductal spreading.
Literature
1.
Wahl R, Cody R, Hutchins G, Mudgett E. Positron emission tomography scanning of primary and metastatic breast cancer with radiolabeled glucose analogue 2-deoxy-2 (18F) fluoro-Dglucose. N Engl J Med. 1991;324:200.PubMed
2.
3.
Avril N, Schelling M, Dose J, Weber WA, Schwaiger M. Utility of PET in breast cancer. Clin Positron Imaging. 1999;2:261–71.PubMedCrossRef
4.
Bombardieri E, Grippa F. PET imaging in breast cancer. Q J Nucl Med. 2001;45:245–56.PubMed
5.
Czernin J. FDG PET in breast cancer: a different view of its clinical use. Mol Imaging Biol. 2002;4:35–45.PubMedCrossRef
6.
Heinisch M, Gallowitsch HJ, Mikosch P, Kresnik E, Kumnig G, Gomez I, et al. Comparison of FDG PET and dynamic contrast enhanced MRI in the evaluation of suggestive breast lesions. Breast. 2003;12:17–22.PubMedCrossRef
7.
Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med. 2004;45 (Suppl 1):4S–14S.PubMed
8.
Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14:260–8.PubMedCrossRef
9.
Kinahan PE, Hasegawa BH, Beyer T. X-ray based attenuation correction for PET/CT scanners. Semin Nucl Med.2003;33:166–79.PubMedCrossRef
10.
Zaidi H, Hasegawa B. Determination of the attenuation map in emission tomography. J Nucl Med. 2003;44:291–315.PubMed
11.
von Schulthess GK. Cost considerations regarding an integrated CT-PET system. Eur Radiol. 2000;10(Suppl 3):S377–80.CrossRef
12.
Holm S, Toft P, Jensen M. Estimation of the noise contributions from blank, transmission and emission scans in PET. IEEE Trans Nucl Sci. 1996;43:2285–91.CrossRef
13.
Beyer T, Kinahan PE, Townsend DW. Optimization of emission and transmission scan duration in 3D whole-body PET. IEEE Trans Nucl Sci. 1997;44:2400–7.CrossRef
14.
Heinisch M, Gallowitsch HJ, Mikosch P, Kresnik E, Kumnig G, Gomez I, et al. Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions. Breast. 2003;12:17–22.PubMedCrossRef
15.
Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, et al. Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28:351–8.PubMedCrossRef
16.
Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495–3502.PubMed
17.
Palmedo H, Bender H, Grünwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. Eur J Nucl Med. 1997;24:1138–45.PubMed
18.
Avril N, Dose J, Janicke DF, Bense S, Ziegler S, Laubenbacher C, et al. Metabolic characterization of breast tumors with positron emission tomography using 18F fluorodeoxyglucose. J Clin Oncol. 1996;14:1848–57.PubMed
19.
Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Gohring U, Schomacker K, et al. Qualitative 18F-FDG PET in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med. 1996;23:618–23.PubMedCrossRef
20.
Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766–74.PubMed
21.
Adler LP, Crowe JP,al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (18F) 2-deoxy-2-fluoro-d-glucose PET. Radiology. 1993;187:743–50.PubMed
22.
Nitzsche EU, Hoh CK, Dalbohm NM, Glaspy JA, Phelps ME, Moser EA, et al. Whole body positron emission tomography in breast cancer. Rofo. 1993;158:293–8.PubMed
23.
Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK, et al. Diagnostic value of positron emission tomography in primary breast cancer. World J Surg. 1998;23:223–8.CrossRef
24.
Tamaki Y, Akashi-Tanaka S, Ishida T, Uematsu T, Sawai Y, Kusama M, et al. 3D imaging of intraductal spread of breast cancer and its clinical application for navigation surgery. Breast Cancer. 2002;9:289–95.PubMedCrossRef
25.
Avril N, Dose J, Janicke F, Ziegler S, Romer W, Weber W, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-d-glucose. J Natl Cancer Inst. 1996;88:1204–9.PubMedCrossRef
26.
Crippa F, Agrest R, Seregni E, Greco M, Pascali C, Bogni A, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med. 1998;39:4–8.PubMed
27.
Early Breast Cancer Trials’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106.
28.
Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelpes ME, Hoh CK. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431–5.PubMed
29.
Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer. 2000;88:2927–33.PubMedCrossRef
30.
Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676–88.PubMed
31.
Schelling M, Avril N, Nähring J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [18F]-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689–95.PubMed
32.
Schwarz JD, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144–50.
Metadata
Title
PET/CT supports breast cancer diagnosis and treatment
Authors
Mitsuhiro Hayashi
Koji Murakami
Testsunari Oyama
Yasushi Domeki
Shingo Hagiwara
Daisuke Katsumata
Masakatsu Sunagawa
Publication date
01-07-2008
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2008
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-008-0051-2

Other articles of this Issue 3/2008

Breast Cancer 3/2008 Go to the issue

Original Article

Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas

Special Feature

Diagnosis of breast cancer: MDCT versus MRI

Erratum: Retraction

Retraction notice to “Age-period-cohort analysis of female breast cancer mortality in Korea”

Special Feature

Current state and future of diagnostic breast imaging

Special Feature

Proton MR spectroscopy of the breast

Special Feature

Current improvements in breast ultrasound, with a special focus on elastography
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits